ClinicalTrials.gg
CompletedNCT01423084Updated Feb 20, 2015Results posted

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

A Phase 3 interventional study of Serogroup B meningococcal vaccine in Meningococcal Disease and Meningococcal Meningitis, sponsored by Novartis. Completed at 13 sites in 2 countries. Open to participants aged 11 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-20.

Primary conditionMeningitis, MeningococcalRegistry: Meningococcal InfectionsReclassifiedWhy we changed it
Registry
Meningococcal Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningococcal Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.

Enrollment
5th of 11
344 · median 250
Started
2011
the only one that year
Phase 3
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
2 of 11
Novartis

Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 3, and was the 4th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup B reference strains (H44/76, 5/99, and NZ98/254) and as measured by ELISA geometric mean concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary vaccination course of two doses administered one month apart.

Read the detailed description

Novartis will consider this study a success if, at one month following the second vaccination, the two-sided 95% CI of the ratio of the hSBA GMTs for each of 3 serogroup B reference strains (H44/76, 5/99, and NZ98/254) and the two-sided 95% CI of the ratio of the ELISA GMCs against vaccine antigen 287-953 are contained within the interval (0.5, 2.0).

03

Conditions studied

  • Meningococcal Disease
  • Meningococcal Meningitis

Browse trials for

Keywords

  • Meningococcal Meningitis
  • prevention, vaccination
  • adolescents
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 344 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningococcal Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects (11-17 years of age inclusive) who have given their written assent and whose parents or legal guardians have given written at the time of enrollment
  • who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period)
  • in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of any serogroup B meningococcal vaccination
  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment
  • Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38.0 °C) within the previous day
  • Antibiotic use within 3 days (72 hours) prior to enrollment
  • Pregnancy or nursing (breastfeeding) mothers
  • Females of childbearing age who have not used or do not plan to use acceptable measures, for the 2 months duration of the study. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry
  • Any serious chronic or progressive disease, Known or suspected impairment/alteration of the immune system
  • Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days
  • History of severe allergic reactions after previous vaccinations or to any vaccine component
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    MenB Lot 1

    MenB vaccine Lot 1: 2 doses administered 1 month apart

    Biological: Serogroup B meningococcal vaccine

  • Active comparator
    MenB Lot 2

    MenB vaccine Lot 2: 2 doses administered 1 month apart

    Biological: Serogroup B meningococcal vaccine

Interventions

  • All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2. A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination

07

What researchers measure

Primary outcomes

  1. Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.

    Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).

    Time frame: One month after the second vaccination (day 61)

  2. ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953

    The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.

    Time frame: One month after the second vaccination (day 61)

Secondary outcomes

  1. Percentage of Subjects in Each Lot With hSBA ≥ 1:5

    The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group

    Time frame: One month after the second vaccination (day 61)

  2. Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.

    The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).

    Time frame: One month after the second vaccination (day 61)

  3. Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953

    The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).

    Time frame: One month after the second vaccination (day 61)

  4. hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.

    The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.

    Time frame: Two weeks after the second vaccination (day 45)

  5. GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.

    The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N. meningitidis serogroup B reference strains at two weeks after last vaccination.

    Time frame: Two weeks after the second vaccination (day 45)

  6. Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.

    The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.

    Time frame: Two weeks after the second vaccination (day 45)

  7. ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.

    The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.

    Time frame: Two weeks after the second vaccination (day 45)

  8. GMR of ELISA GMCs Against Antigen 287-953 at Day 45.

    The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).

    Time frame: Two weeks after the second vaccination (day 45)

  9. Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)

    Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.

    Time frame: From day 1 to day 7 after any vaccination

  10. Number of Subjects Reporting Unsolicited AEs

    Number of subjects reporting any Unsolicited AEs after any vaccination.

    Time frame: From day 1 to day 7 after any vaccination.

  11. Number of Subjects Reporting SAEs and AE Leading to Withdrawal

    Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject's withdrawal from the study after any vaccination.

    Time frame: Throughout the study period.

08

Results

Posted Feb 20, 2015
Limitations and caveats
None reported

Participant flow

Actual start date of recruiting was 30 August 2011. Subjects were recruited from 7 centres in Canada and 6 centres in Australia.

Participant flow — Overall Study
Milestone4CMenB_Rosia4CMenB_Siena
Started170174
Completed168170
Not completed24
Withdrew: Adverse event01
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryHuman Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.

Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).

Time frame:
One month after the second vaccination (day 61)
Reported as:
Geometric mean · Titers
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.
Titers4CMenB_Rosia4CMenB_Siena
H44/76 strain111 (96 to 129)111 (96 to 128)
NZ98/254 strain9.27 (7.44 to 12)11 (9.22 to 14)
5/99 strain (N=152)183 (160 to 209)199 (174 to 227)
Statistical analysis
  • 4CMenB_Rosia vs 4CMenB_Siena · Between groups ratio: 1 · 95% CI 0.82 to 1.23
  • 4CMenB_Rosia vs 4CMenB_Siena · Between groups ratio: 0.92 · 95% CI 0.77 to 1.1
  • 4CMenB_Rosia vs 4CMenB_Siena · Between groups ratio: 0.81 · 95% CI 0.6 to 1.09
SecondaryPercentage of Subjects in Each Lot With hSBA ≥ 1:5

The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group

Time frame:
One month after the second vaccination (day 61)
Reported as:
Number · Percentage of subjects
Percentage of Subjects in Each Lot With hSBA ≥ 1:5
Percentage of subjects4CMenB_Rosia4CMenB_Siena
H44/76 strain (N=151)99 (96 to 100)99 (96 to 100)
NZ98/254 strain (N=151)70 (62 to 77)79 (72 to 86)
5/99 strain100 (98 to 100)100 (98 to 100)
SecondaryGeometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.

The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).

Time frame:
One month after the second vaccination (day 61)
Reported as:
Geometric mean · Ratio of GMTs
Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.
Ratio of GMTs4CMenB_Rosia4CMenB_Siena
H44/76 strain (N=151)104 (89 to 121)107 (92 to 124)
NZ98/254 strain (N=151)8.63 (6.99 to 11)11 (8.99 to 14)
5/99156 (133 to 183)167 (143 to 195)
SecondaryGeometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953

The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).

Time frame:
One month after the second vaccination (day 61)
Reported as:
Geometric mean · Ratio of GMTs
Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953
Ratio of GMTs4CMenB_Rosia4CMenB_Siena
Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953122 (103 to 143)153 (131 to 179)
SecondaryhSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.

The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.

Time frame:
Two weeks after the second vaccination (day 45)
Reported as:
Geometric mean · Titers
hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.
Titers4CMenB_RosiaMenB Lot 2
H44/76 strain187 (152 to 229)171 (139 to 210)
NZ98/254 strain14 (10 to 18)20 (15 to 27)
5/99 strain254 (206 to 314)339 (273 to 420)
SecondaryGMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.

The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N. meningitidis serogroup B reference strains at two weeks after last vaccination.

Time frame:
Two weeks after the second vaccination (day 45)
Reported as:
Geometric mean · Ratio of GMTs
GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.
Ratio of GMTs4CMenB_Rosia4CMenB_Siena
H44/76 strain174 (138 to 219)157 (124 to 199)
NZ98/25413 (9.87 to 17)20 (15 to 26)
5/99 strain214 (161 to 284)243 (183 to 325)
SecondaryPercentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.

The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.

Time frame:
Two weeks after the second vaccination (day 45)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.
Percentage of subjects4CMenB_Rosia4CMenB_Siena
H44/76 strain100 (95 to 100)100 (95 to 100)
NZ98/254 strain84 (74 to 92)96 (88 to 99)
5/99 strain100 (95 to 100)100 (95 to 100)
SecondaryELISA GMCs Against Vaccine Antigen 287-953 at Day 45.

The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.

Time frame:
Two weeks after the second vaccination (day 45)
Reported as:
Geometric mean · IU/ml
ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.
IU/ml4CMenB_Rosia4CMenB_Siena
ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.3742 (2994 to 4676)4798 (3825 to 6019)
PrimaryELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953

The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.

Time frame:
One month after the second vaccination (day 61)
Reported as:
Geometric mean · IU/ml
ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953
IU/ml4CMenB_Rosia4CMenB_Siena
ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-9532729 (2338 to 3186)3291 (2829 to 3828)
Statistical analysis
  • 4CMenB_Rosia vs 4CMenB_Siena · Between groups ratio: 0.83 · 95% CI 0.67 to 1.02
SecondaryGMR of ELISA GMCs Against Antigen 287-953 at Day 45.

The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).

Time frame:
Two weeks after the second vaccination (day 45)
Reported as:
Geometric mean · Ratio of GMTs
GMR of ELISA GMCs Against Antigen 287-953 at Day 45.
Ratio of GMTs4CMenB_Rosia4CMenB_Siena
GMR of ELISA GMCs Against Antigen 287-953 at Day 45.166 (130 to 213)217 (169 to 279)
SecondaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)

Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.

Time frame:
From day 1 to day 7 after any vaccination
Reported as:
Number · Number of subjects
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)
Number of subjects4CMenB_Rosia4CMenB_Siena
Any local163170
Induration6575
Pain162170
Erythema111111
Swelling8074
Any systemic136150
Nausea4956
Fatigue7585
Myalgia99118
Arthralgia2844
Headache7589
Fever (>= 38C)85
Rash1116
Any other8796
Use of analgesics8292
SecondaryNumber of Subjects Reporting Unsolicited AEs

Number of subjects reporting any Unsolicited AEs after any vaccination.

Time frame:
From day 1 to day 7 after any vaccination.
Reported as:
Number · Number of subjects
Number of Subjects Reporting Unsolicited AEs
Number of subjects4CMenB_Rosia4CMenB_Siena
Number of Subjects Reporting Unsolicited AEs5655
SecondaryNumber of Subjects Reporting SAEs and AE Leading to Withdrawal

Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject's withdrawal from the study after any vaccination.

Time frame:
Throughout the study period.
Reported as:
Number · Number of subjects
Number of Subjects Reporting SAEs and AE Leading to Withdrawal
Number of subjects4CMenB_Rosia4CMenB_Siena
Serious Adverse Events00
Adverse Events01

Adverse events

Collected over SAEs were collected from day 1 through study termination, other AEs were collected from day 1 to day 7 after vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
4CMenB_Rosia—0/169 (0%)165/169 (97.6%)
4CMenB_Siena—0/173 (0%)171/173 (98.8%)
Most frequent other events
Most frequent other events
Event4CMenB_Rosia4CMenB_Siena
injection site painGeneral disorders162/169170/173
myalgiaMusculoskeletal and connective tissue disorders99/169118/173
injection site erythemaGeneral disorders111/169111/173
HeadacheNervous system disorders75/16989/173
FatigueGeneral disorders75/16985/173
injection site swellingInvestigations80/16974/173
injection site indurationGeneral disorders65/16975/173
nauseaGastrointestinal disorders49/16956/173
arthralgiaMusculoskeletal and connective tissue disorders28/16945/173
rashSkin and subcutaneous tissue disorders11/16916/173

Baseline characteristics

adolescents aged 11-17 years

Age, Continuous
Age, Continuous(years)4CMenB_Rosia4CMenB_SienaTotal
Mean13.6 ± 1.913.8 ± 1.813.7 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)4CMenB_Rosia4CMenB_SienaTotal
Female7282154
Male9892190
09

Study locations

13 sites
  • Royal Children's Hospital
    Herston, Queensland 4029, Australia
  • AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre
    Kippa-Ring, Queensland 4021, Australia
  • AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street
    Sherwood, Queensland 4075, Australia
  • Women's and Children's Hospital, 72 King William Road
    North Adelaide, South Australia 5006, Australia
  • Murdoch Children's Research Institute-Level 5, 207 Bouverie St-University of Melbourne
    Melbourne, Victoria 3010, Australia
  • Telethon Institute for Child Heath Research-cnr
    Hamilton Street and Roberts Road-Subiaco, Western Australia 6008, Australia
  • TASC Research Services, 1-15243 91st Avenue
    Surrey, British Columbia V3R 8P8, Canada
  • Colchester Regional Hospital Colchester Research Group, 68 Robie Street
    Truro, Nova Scotia B2N 1L2, Canada
  • Albion Finch Medical Centre, 1620 Albion Road, Suite 106
    Etobicoke, Ontario M9V 4B4, Canada
  • Medicor Research Inc, 359 Riverside, Suite 200
    Sudbury, Ontario P3E 1H5, Canada
  • SKDS Research Inc, 221-679 Davis Dr.Newmarket
    Toronto, Ontario L3Y 5G8, Canada
  • Dr. Hartley Garfield Medicine Professional Corporation, 790 Bay Street, Suite 540
    Toronto, Ontario M5G 1N8, Canada
  • Devonshire Clinical Research INC, 423 Devonshire Ave., Suite 301
    Woodstock, Ontario N4S 5P5, Canada
10

References and documents

Publications

  • Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015 Sep 22;33(39):5217-24. doi: 10.1016/j.vaccine.2015.06.103. Epub 2015 Jul 29. PubMed 26232542 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2011
First posted
Aug 25, 2011
Start
Aug 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Feb 20, 2015
Last update
Feb 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01423084
Lead sponsor
Novartis
Collaborators
Novartis Vaccines
Responsible party
Sponsor
First posted
Aug 25, 2011
Start date
Aug 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Feb 20, 2015
Last update
Feb 20, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion